<?xml version='1.0' encoding='utf-8'?>
<document id="16108826"><sentence text="Development and validation of UPLC-MS/MS method for studying the pharmacokinetic interaction of dasabuvir and tamoxifen, 4-hydroxytamoxifen in Wistar rats."><entity charOffset="96-105" text="dasabuvir" /><entity charOffset="110-119" text="tamoxifen" /><entity charOffset="121-139" text="4-hydroxytamoxifen" /></sentence><sentence text="Hepatitis C virus (HCV) is the main cause of chronic hepatitis and probably liver cirrhosis" /><sentence text=" Dasabuvir (DSV) is a direct-acting antiviral agent with efficiency in managing HCV"><entity charOffset="1-10" text="Dasabuvir" /><entity charOffset="12-15" text="DSV" /></sentence><sentence text=" The anti-viral activity of the anti-estrogen drug tamoxifen (TAM) suggested the synergistic effect of DSV and TAM for blocking the replication of HCV"><entity charOffset="51-60" text="tamoxifen" /><entity charOffset="62-65" text="TAM" /></sentence><sentence text=" However, being substrates and inhibitors of efflux transporters (TAM inhibits P-gp, DSV inhibits P-gp and BCRP), there is a possibility for a pharmacokinetic (PK) drug-drug interaction" /><sentence text=" In this work, a new UPLC-MS/MS method was developed and validated for the simultaneous determination of TAM, its active metabolite 4-hydroxy tamoxifen (TOH), and DSV in rat plasma"><entity charOffset="132-151" text="4-hydroxy tamoxifen" /><entity charOffset="153-156" text="TOH" /><entity charOffset="163-166" text="DSV" /></sentence><sentence text=" The method was applied to investigate the PK interaction between DSV and TAM/TOH following the co-administration of DSV and TAM to Wistar rats" /><sentence text=" Chromatographic analysis was performed on Waters BEHTM C18 column using a mobile phase of acetonitrile/water containing 0"><entity charOffset="91-103" text="acetonitrile" /></sentence><sentence text="1% formic acid (80: 20, v/v)"><entity charOffset="3-14" text="formic acid" /></sentence><sentence text=" The method allowed the determination of concentration ranges 20-1000, 0" /><sentence text="1-500, 0" /><sentence text="5-500â€‰ng/mL for DSV, TAM, and TOH, respectively" /><sentence text=" Unexpectedly, results revealed the absence of PK interactions between DSV and TAM/TOH, compared with their single administration, suggesting the safety of co-administering DSV/TAM as an anti-viral combination without the need of dosage adjustment"><entity charOffset="83-86" text="TOH" /></sentence><sentence text="" /></document>